

**Appendix Table F45. Exploring heterogeneity in discontinuation rates due to adverse effects after duloxetine compared to placebo (results from meta-regression)**

Variable	Coefficient	Standard error	T statistic	P>t	Lower 95% CI	Upper 95% CI
Daily dose	0.01	0.004	1.83	0.11	-0.01	0.02
Constant	-.49	0.34	-1.47	0.19	-1.69	0.69
Conflict of interest	0.03	0.06	0.52	0.62	-0.17	0.23
Constant	0.08	0.10	0.78	0.46	-0.27	0.42
Adequacy of randomization	0.06	0.06	1.00	0.36	-0.16	0.28
Allocation concealment	0.08	0.07	1.20	0.28	-0.17	0.33
Constant	-0.12	0.18	-0.64	0.55	-0.80	0.57
Presence of mixed UI	-0.04	0.14	-0.26	0.81	-0.70	0.63
Inclusion of minorities	0.00	0.09	0.00	1.00	-0.43	0.43
Presence of those who failed prior treatments	0.06	0.14	0.45	0.68	-0.59	0.71
Presence of women with surgical risk factors for UI	-0.05	0.11	-0.42	0.70	-0.57	0.48
Constant	0.15	0.08	1.90	0.13	-0.21	0.50